Attached files
| file | filename |
|---|---|
| 10-K - Altimmune, Inc. | v216624_10k.htm |
| EX-21 - Altimmune, Inc. | v216624_ex21.htm |
| EX-31.1 - Altimmune, Inc. | v216624_ex31-1.htm |
| EX-32.2 - Altimmune, Inc. | v216624_ex32-2.htm |
| EX-31.2 - Altimmune, Inc. | v216624_ex31-2.htm |
| EX-32.1 - Altimmune, Inc. | v216624_ex32-1.htm |
| EX-10.30(5) - Altimmune, Inc. | v216624_ex10-305.htm |
| EX-10.30(4) - Altimmune, Inc. | v216624_ex10-304.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-146463),
(2) Registration Statement (Form S-3 No. 333-155692),
(3) Registration Statement (Form S-8 No. 333-156371) pertaining to the 2007 Long-Term Incentive Compensation Plan,
(4) Registration Statement (Form S-3 No. 333-156997),
(5) Registration Statement (Form S-3 No. 333-124712), and
(6) Registration Statement (Form S-3 No. 333-161587),
of PharmAthene, Inc. and in the related Prospectuses of our report dated March 31, 2011, with respect to the consolidated financial statements of PharmAthene, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2010.
/s/ Ernst & Young LLP
McLean, Virginia
March 31, 2011